Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integral Diagnostics Ltd. ( (AU:IDX) ) has issued an announcement.
Integral Diagnostics Limited has disclosed a change in the interests of director James Tobias Hall, who holds his stake indirectly via SF Nominees Pty Ltd as trustee for a self-managed super fund. The filing notes that the director is both a director and shareholder of the trustee and a beneficiary of the trust structure through which the shares are held.
On 9 March 2026, Hall acquired 10,000 fully paid ordinary shares in Integral Diagnostics on-market at $2.25 per share, increasing his holding from 200,492 to 210,492 shares. The company reported that there were no related changes in contracts or trades during a closed period, indicating the transaction occurred under normal trading conditions and in compliance with governance requirements.
The most recent analyst rating on (AU:IDX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited operates in the medical imaging and diagnostics sector, providing radiology and related diagnostic imaging services. The company serves healthcare providers and patients through a network of imaging facilities, positioning it within the broader healthcare services and diagnostics market in Australia.
Average Trading Volume: 700,561
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$879.6M
See more data about IDX stock on TipRanks’ Stock Analysis page.